Table 1

Demographics and disease characteristics at baseline

Population A
n=1017
Population B
n=669
Demographics
 Age, years45.7±14.847.9±14.5
 Females, n (%)561 (55.2)394 (58.9)
 BMI, kg/m2 25.6±4.325.8±4.2
 Current daily smoker, n (%)292 (29.0)202 (30.3)
 Ever smoker, n (%)613 (60.8)419 (62.9)
 Coffee ≥5 cups/day, n (%)247 (24.6)169 (25.5)
 Education, college/university, n (%)451 (44.5)287 (42.9)
Disease characteristics
 Duration of joint swelling in days35.0 (13.0–66.5)41.0 (18.0–72.0)
 ACPA positive, n (%)178 (17.8)148 (22.3)
 RF positive, n (%)177 (17.7)153 (23.0)
 ACPA and/or RF positive, n (%)230 (23.0)187 (28.2)
 ESR, mm24.0 (12.0–47.0)26.0 (13.0–47.0)
 CRP, mg/L16.0 (5.0–45.0)15.7 (5.0–43.0)
 Joint pain VAS, mm53.0 (30.3–71.0)54.0 (34.0–72.0)
 Fatigue VAS, mm41.5 (10.0–67.0)45.0 (12.0–67.0)
 Morning stiffness >1 hour, n (%)508 (56.5)349 (59.0)
 Patient’s global VAS, mm53.0 (35.0–70.0)55.0 (37.0–73.0)
 Assessor’s global VAS, mm34.0 (22.0–50.0)36.0 (23.0–52.0)
 SF-36, physical components summary score32.8 (25.5–39.8)32.1 (24.8–39.0)
 SF-36, mental components summary score49.5 (40.2–57.2)48.9 (40.4–56.9)
 HAQ-DI0.75 (0.25–1.25)0.88 (0.38–1.38)
 28 Tender joint count2.0 (1.0–4.0)2 (1.0–5.0)
 68 Swollen joint count2.0 (1.0–6.0)3 (1.0–7.0)
 DAS284.1 (3.2–5.0)4.3 (3.4–5.1)
  • Continuous data are presented as median (25th–75th percentile) or mean±SD, counts as numbers and valid percentages.

  • ACPA, anticitrullinated protein antibodies; BMI, body mass index; CRP, C reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; population A, patients with any follow-up time; population B, patients with data at the 2-year follow-up visit; RF, rheumatoid factor; SF-36, Short-Form 36; VAS, visual analogue scale.